消化器内科 論文(2021年)
英語論文
| 著者 | タイトル | ジャーナル |
| Kawai S, Takeshima N, Hayasaka Y, Notsu A, Yamazaki M, Kawabata T, Yamazaki K, Mori K, Yasui H. | Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis. | BMC Cancer. |
| Ari Nishimura, Tomoya Yokota, Satoshi Hamauchi, Yusuke Onozawa, Hiromichi Shirasu, Takanori Kawabata, Hirofumi Ogawa, Tsuyoshi Onoe, Yoshiyuki Iida, Takashi Mukaigawa, Hirofumi Yasui | Incurable locoregional disease is a strong poor prognostic factor in recurrent or metastatic squamous cell carcinoma of the head and neck | Int J Clin Oncol. |
| Yamazaki K, Yamanaka T, Shiozawa M et al. | Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial. | Ann Oncol. |
| Tomoya Yokota, Sadamoto Zenda, Ichiro Ota, Tomoko Yamazaki, Takuhiro Yamaguchi, Takenori Ogawa, Hiroyuki Tachibana, Takashi Toshiyasu, Akihiro Homma, Tempei Miyaji, Tomoe Mashiko, Satoshi Hamauchi, Kuniko Tominaga, Shinobu Ishii, Yui Otani, Noriko Orito, Yosuke Uchitomi | Phase 3 Randomized Trial of Topical Steroid Versus Placebo for Prevention of Radiation Dermatitis in Patients With Head and Neck Cancer Receiving Chemoradiation | Int J Radiat Oncol Biol Phys. |
| Takahashi T, Yamazaki K, Oki E et al. | Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7. | ESMO Open. |
| Tomoya Yokota, Yosuke Ota, Hirofumi Fujii, Takeshi Kodaira, Mototsugu Shimokawa, Torahiko Nakashima, Nobuya Monden, Akihiro Homma, Shinya Ueda, Tetsuo Akimoto | Real-world clinical outcomes and prognostic factors in Japanese patients with recurrent or metastatic squamous cell carcinoma of head and neck treated with chemotherapy plus cetuximab: a prospective observation study (JROSG12-2). | Int J Clin Oncol. |
| Yamazaki K, Yuki S, Oki E et al. | Real-World Evidence on Second-Line Treatment of Metastatic Colorectal Cancer Using Fluoropyrimidine, Irinotecan, and Angiogenesis Inhibitor. | Clin Colorectal Cancer. |
| Tomoya Yokota, Tetsuro Onitsuka, Satoshi Hamauchi, Hiromichi Shirasu, Yusuke Onozawa, Yoshiyuki Iida, Tomoyuki Kamijo, Takashi Mukaigawa, Shinichi Okada, Yuki Irifune, Kotaro Ishida, Hirofumi Ogawa, Tsuyoshi Onoe | Triplet induction chemotherapy followed by less invasive surgery without reconstruction for human papillomavirus-associated oropharyngeal cancers: Why is it successful or unsuccessful? | Int J Clin Oncol. |
| Yamazaki K, Yoshimura A, Miyahara S, Sugi S, Itono M, Kondo M, Tsuji N, Shimizu M, Fukushima R, Kishimoto M. | Evaluation of cerebral blood flow in the hippocampus, thalamus, and basal ganglia and the volume of the hippocampus in dogs before and during treatment with prednisolone. | Am J Vet Res. |
| Yamamoto S, Nagashima K, Kawakami T, Mitani S, Komoda M, Tsuji Y, Izawa N, Kawakami K, Yamamoto Y, Makiyama A, Yamazaki K, Masuishi T, Esaki T, Nakajima TE, Okuda H, Moriwaki T, Boku N. | Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer. | BMC Cancer. |
| Taniguchi H, Yoshino T, Yamaguchi K, Yamazaki K, Nixon AB, Tabernero J, Van Cutsem E, Robling KR, Abada PB, Hozak RR, Siegel R, Fill JA, Wijayawardana S, Walgren RA, Giles B, Jones A, Pitts KR, Drove N, Muro K. | Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study. | Curr Med Res Opin. |
| Okuyama H, Kagawa Y, Masuishi T, Mishima S, Shirasu H, Ando K, Yuki S, Muro K, Yoshino T, Yamazaki K, Oki E, Komatsu Y, Tsuji A. | Infusion-related reaction to ramucirumab plus FOLFIRI in patients with advanced colorectal cancer. | Int J Clin Oncol. |
| Niisato Y, Moriwaki T, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Shimada Y. | Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment. | Anticancer Res. |
| Nakajima H, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Negoro Y, Komoda M, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Ando K, Yuki S, Okuyama H, Kusaba H, Sakai D, Okamoto K, Tamura T, Yamashita K, Gosho M, Moriwaki T. | Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment. | Front Oncol. |
| Nakajima H, Kotani D, Bando H, Kato T, Oki E, Shinozaki E, Sunakawa Y, Yamazaki K, Yuki S, Nakamura Y, Yamanaka T, Yoshino T, Ohta T, Taniguchi H, Kagawa Y. | REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer. | BMC Cancer. |
| Miura Y, Ando M, Yamazaki K, Hironaka S, Boku N, Muro K, Hyodo I. | Time-dependent discrepancies between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy in patients with metastatic colorectal cancer who received mFOLFOX6 plus bevacizumab: a post hoc analysis (WJOG4407GSS2). | Support Care Cancer. |
| Kotani D, Yoshino T, Kotaka M, Kawazoe A, Masuishi T, Taniguchi H, Yamazaki K, Yamanaka T, Oki E, Muro K, Komatsu Y, Bando H, Satake H, Kato T, Tsuji A. | Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II study. | Invest New Drugs. |
| Iveson TJ, Sobrero AF, Yoshino T, Souglakos I, Ou FS, Meyers JP, Shi Q, Grothey A, Saunders MP, Labianca R, Yamanaka T, Boukovinas I, Hollander NH, Galli F, Yamazaki K, Georgoulias V, Kerr R, Oki E, Lonardi S, Harkin A, Rosati G, Paul J. | Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer | J Clin Oncol |
| Hasegawa H, Taniguchi H, Nakamura Y, Kato T, Fujii S, Ebi H, Shiozawa M, Yuki S, Masuishi T, Kato K, Izawa N, Moriwaki T, Oki E, Kagawa Y, Denda T, Nishina T, Tsuji A, Hara H, Esaki T, Nishida T, Kawakami H, Sakamoto Y, Miki I, Okamoto W, Yamazaki K, Yoshino T. | FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer | Cancer Sci |
| Inoue H, Todaka A, Yamazaki K, Fushiki K, Shirasu H, Kawakami T, Tsushima T, Hamauchi S, Yokota T, Machida N, Fukutomi A, Onozawa Y, Andoh A, Yasui H. | Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer | Invest New Drugs |
| Chida K, Kotani D, Masuishi T, Kawakami T, Kawamoto Y, Kato K, Fushiki K, Sawada K, Kumanishi R, Shirasu H, Matsubara Y, Yuki S, Komatsu Y, Yamazaki K, Yoshino T. | The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study | Oncologist |
| Kato T, Kagawa Y, Kuboki Y, Gamoh M, Komatsu Y, Yasui H, Satake H, Oki E, Tanioka H, Kotaka M, Makiyama A, Denda T, Goto M, Yoshino T, Yamazaki K, Soeda J, Shibuya K, Iwata M, Oba K, Yamaguchi K. | Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study | Int J Clin Oncol |
| Chida K, Kotani D, Moriwaki T, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Komoda M, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Ando K, Yuki S, Okita Y, Kusaba H, Sakai D, Okamoto K, Tamura T, Yamashita K, Gosho M, Shimada Y. | Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS) | Front Oncol |
| Takinami M, Ono A, Kawabata T, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Kenmotsu H, Naito T, Murakami H, Endo M, Kiyohara Y, Yasui H, Niwakawa M, Takahashi T. | Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis | Invest New Drugs |
| Kenmotsu H, Notsu A, Mori K, Omori S, Tsushima T, Satake Y, Miki Y, Abe M, Ogiku M, Nakamura T, Takagi M, Ochiai H, Yasui H, Takahashi T. | Cumulative incidence of venous thromboembolism in patients with advanced cancer in prospective observational study | Cancer Med |
| Haneda R, Booka E, Ishii K, Kikuchi H, Hiramatsu Y, Kamiya K, Ogawa H, Yasui H, Takeuchi H, Tsubosa Y. | Evaluation of Definitive Chemoradiotherapy Versus Radical Esophagectomy in Clinical T1bN0M0 Esophageal Squamous Cell Carcinoma | World J Surg |
| Satoh T, Kato K, Ura T, Hamamoto Y, Kojima T, Tsushima T, Hironaka S, Hara H, Iwasa S, Muro K, Yasui H, Minashi K, Yamaguchi K, Ohtsu A, Doki Y, Matsumura Y, Kitagawa Y. | Five-year follow-up of nivolumab treatment in Japanese patients with esophageal squamous-cell carcinoma (ATTRACTION-1/ONO-4538-07) | Esophagus |
| Booka E, Haneda R, Ishii K, Tsushima T, Yasui H, Tsubosa Y. | The Negative Impact of Preoperative Chemotherapy on Survival After Esophagectomy for Vulnerable Elderly Patients with Esophageal Cancer | Ann Surg Oncol |
| Arai H, Kawahira M, Yasui H, Masuishi T, Muro K, Nakajima TE. | Second-line chemotherapy using taxane in patients with advanced gastric cancer who presented with severe peritoneal metastasis: a multicenter retrospective study | Int J Clin Oncol |
| Yamaguchi K, Fuse N, Komatsu Y, Fujii H, Hironaka S, Omuro Y, Muro K, Yasui H, Ueda S, Nishina T, Watanabe M, Ohtsu A. | Phase II study of cetuximab plus S-1/cisplatin therapy in Japanese patients with advanced gastric cancer | Jpn J Clin Oncol |
| Niihara M, Tsubosa Y, Yamashita A, Mori K, Tsumaki H, Onozawa Y, Fukuda H. | Supplemental enteral tube feeding nutrition after hospital discharge of esophageal cancer patients who have undergone esophagectomy | Esophagus |
| Oliveira TB, Mesía R, Falco A, Hsieh JC, Yokota T, Saada-Bouzid E, Schmitz S, Elicin O, Giacomelli L, Bossi P. | Defining the needs of patients with recurrent and/or metastatic head and neck cancer: An expert opinion | Crit Rev Oncol Hematol |
| Okano S, Homma A, Kiyota N, Tahara M, Hanai N, Asakage T, Matsuura K, Ogawa T, Saito Y, Sano D, Kodaira T, Motegi A, Yasuda K, Takahashi S, Tanaka K, Onoe T, Yokota T, Imamura Y, Ariizumi Y, Akimoto T, Hayashi R. | Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck | Jpn J Clin Oncol |
| Yokota T. | [Ⅱ. Neoadjuvant and Adjuvant Therapy for Esophageal Cancer] | Gan To Kagaku Ryoho |
| Booka E, Tsubosa Y, Yokota T, Mayanagi S, Ishii K, Urakami K, Ohshima K, Ohnami S, Nagashima T, Yamaguchi K. | Whole exome sequencing and deep sequencing of esophageal squamous cell carcinoma and adenocarcinoma in Japanese patients using the Japanese version of the Genome Atlas, JCGA | Esophagus |
| Hanai N, Shimizu Y, Kariya S, Yasumatsu R, Yokota T, Fujii T, Tsukahara K, Yoshida M, Hanyu K, Ueda T, Hirakawa H, Takahashi S, Ono T, Sano D, Yamauchi M, Watanabe A, Omori K, Yamazaki T, Monden N, Kudo N, Arai M, Sakurai D, Asakage T, Doi I, Yamada T, Homma A. | Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study | Int J Clin Oncol |
| Kariya S, Shimizu Y, Hanai N, Yasumatsu R, Yokota T, Fujii T, Tsukahara K, Yoshida M, Hanyu K, Ueda T, Hirakawa H, Takahashi S, Ono T, Sano D, Yamauchi M, Watanabe A, Omori K, Yamazaki T, Monden N, Kudo N, Arai M, Yonekura S, Asakage T, Fujiwara A, Yamada T, Homma A. | Effectiveness of nivolumab affected by prior cetuximab use and neck dissection in Japanese patients with recurrent or metastatic head and neck cancer: results from a retrospective observational study in a real-world setting | Int J Clin Oncol |
| Hanai N, Shimizu Y, Kariya S, Yasumatsu R, Yokota T, Fujii T, Tsukahara K, Yoshida M, Hanyu K, Ueda T, Hirakawa H, Takahashi S, Ono T, Sano D, Yamauchi M, Watanabe A, Omori K, Yamazaki T, Monden N, Kudo N, Arai M, Sakurai D, Asakage T, Doi I, Yamada T, Homma A. | Correction to: Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real‑world clinical practice: a multicentre retrospective clinical study | Int J Clin Oncol |
| Tezuka K, Okamura Y, Sugiura T, Ito T, Yamamoto Y, Ashida R, Ohgi K, Otsuka S, Todaka A, Fukutomi A, Uesaka K. | Predictive factors of survival in patients with borderline resectable pancreatic cancer who received neoadjuvant therapy | Pancreatology |
| Takahashi H, Ikeda M, Shiba S, Imaoka H, Todaka A, Shioji K, Yane K, Kojima Y, Kobayashi S, Asagi A, Ozaka M, Takada R, Nagashio Y, Horiguchi S, Kasuga A, Suzuki E, Terashima T, Ueno M, Morizane C, Furuse J. | Multicenter Retrospective Analysis of Chemotherapy for Advanced Pancreatic Acinar Cell Carcinoma: Potential Efficacy of Platinum- and Irinotecan-Containing Regimens | Pancreas |
| Ueno M, Morizane C, Okusaka T, Mizusawa J, Kataoka T, Ikeda M, Ozaka M, Okano N, Sugimori K, Todaka A, Shimizu S, Mizuno N, Yamamoto T, Sano K, Tobimatsu K, Katanuma A, Miyamoto A, Yamaguchi H, Nishina T, Shirakawa H, Kojima Y, Oono T, Kawamoto Y, Furukawa M, Iwai T, Sudo K, Miyakawa H, Yamashita T, Yasuda I, Takahashi H, Kato N, Shioji K, Shimizu K, Nakagohri T, Kamata K, Ishii H, Furuse J; members of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG).. | Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113 | Sci Rep |
| Ioka T, Furuse J, Fukutomi A, Mizusawa J, Nakamura S, Hiraoka N, Ito Y, Katayama H, Ueno M, Ikeda M, Sugimori K, Okano N, Shimizu K, Yanagimoto H, Okusaka T, Ozaka M, Todaka A, Nakamori S, Tobimatsu K, Sata N, Kawashima Y, Hosokawa A, Yamaguchi T, Miyakawa H, Hara H, Mizuno N, Ishii H; Hepatobiliary and Pancreatic Oncology Group (HBPOG) of Japan Clinical Oncology Group (JCOG). | Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group trial, JCOG1106 | Jpn J Clin Oncol |
| Fukahori M, Shibata M, Hamauchi S, Kasamatsu E, Machii K. | A retrospective cohort study to investigate the incidence of cancer-related weight loss during chemotherapy in gastric cancer patients | Support Care Cancer |
| Jogo T, Nakamura Y, Shitara K, Bando H, Yasui H, Esaki T, Terazawa T, Satoh T, Shinozaki E, Nishina T, Sunakawa Y, Komatsu Y, Hara H, Oki E, Matsuhashi N, Ohta T, Kato T, Ohtsubo K, Kawakami T, Okano N, Yamamoto Y, Yamada T, Tsuji A, Odegaard JI, Taniguchi H, Doi T, Fujii S, Yoshino T. | Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer | Clin Cancer Res |
| Takeuchi M, Imamura CK, Booka E, Takeuchi H, Mizukami T, Kawakami T, Funakoshi T, Wakuda K, Aoki Y, Hamamoto Y, Kitago M, Kawakubo H, Boku N, Tanigawara Y, Kitagawa Y. | Prospective evaluation and refinement of an S-1 dosage formula based on renal function for clinical application | Cancer Sci |
和文論文
| 著者 | タイトル | ジャーナル | |
| 濱内 諭 | 【がん悪液質の治療-グレリン様作用薬アナモレリン塩酸塩の登場-】グレリン様作用薬アナモレリン塩酸塩の位置づけ アナモレリン塩酸塩導入のポイント 消化器がん症例の場合 | Progress in Medicine | (0287-3648)41巻11号 Page1115-1120 |
| 横田 知哉 | Upper G.I.Cancer 食道・胃 癌 II.食道癌に対する補助療法の展望 | 癌と化学療法 | (0385-0684)48巻9号 Page1115-1120 |
| 戸髙 明子 | 【腫瘍内科と他領域】周術期治療の進歩 膵臓がんの術前術後療法について | 腫瘍内科 | (1881-6568)28巻5号 Page526-530 |
| 戸髙 明子 | 【膵・胆道癌における薬物療法のすべて】がん薬物療法のエビデンス 膵癌根治切除後の術後補助療法 | 胆と膵 | (0388-9408)42巻臨増特大 Page1101-1104 |
| 西村 在、横田 知哉 | 【分子標的薬と耳鼻咽喉科】分子標的薬の作用機序 抗体製剤 | JOHNS | (0910-6820)37巻12号 Page1515-1517 |
| 伏木 邦博、山崎 健太郎 | 結腸がん術後補助化学療法における最新のエビデンスからみた最適な治療戦略 | 腫瘍内科 | (1881-6568)27巻6号 Page721-728 |
| 白数 洋充 | 【消化管がん】血中循環腫瘍DNAスクリーニングに基づく術後MRD(minimal residual disease)に対する臨床開発の現状と展望 | 腫瘍内科 | (1881-6568)27巻6号 Page690-696 |
| 伏木 邦博、戸髙 明子 | 【切除可能膵癌に対する標準治療:術前治療の意義】切除可能膵癌に対する術前GS療法の安全性と忍容性 | 膵臓 | (0913-0071)36巻1号 Page36-41 |
| 戸髙 明子 | 【消化器領域のがん薬物療法-最近の動向-】膵癌に対する薬物療法 | 消化器内科 | 3巻3号 Page44-50 |
| 伏木 邦博、山崎 健太郎 | 【外科医のための-悪性腫瘍補助療法のすべて】総論 B型肝炎ウイルスの再活性化と対策 | 臨床外科 | (0386-9857)76巻2号 Page144-148 |
| 伏木 邦博、對馬 隆浩 | 【固形がんに対する免疫療法と分子標的治療の進歩】胃がんおよび食道がんの免疫療法と分子標的治療の進歩 | がん分子標的治療 | (1347-6955)18巻2号 Page144-150 |